EW Stock Analysis: Buy, Sell, or Hold?
EW - Edwards Lifesciences Corp
$91.60
-0.96 (-1.04%)
âŧ
5d:
+2.1%
30d:
+4.28%
90d:
+12.61%
WAIT
LOW Confidence
Analysis Updated: Aug 14, 2026 12:00 AM ET
Earnings: Oct 29, 2026
Get Alerted When EW Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: EW is fairly priced but lacks strong directional signals. At 1.0% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: EW is fairly priced but lacks strong directional signals. At 1.0% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$125.48
Based on 8.3% avg growth
INTRINSIC VALUE TODAY
$77.92
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: EW is currently trading at $91.60, which is considered slightly high relative to its 30-day fair value range of $85.13 to $92.54. The stock's valuation (Forward PE: 27.1) is in line with its historical norms (26.3). At these levels, the market is pricing in 1.0% annual earnings growth.
Technical Outlook: Technically, EW is in a strong uptrend. The price is approaching resistance at $93.91. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: EW scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $100.96 (+10.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EW is in a strong uptrend. The price is approaching resistance at $93.91. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: EW scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $100.96 (+10.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$85.13 -
$92.54
Company Quality Score
39/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
43.8%
Protect Your Profits
Holding EW? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Weak technical setup (5/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($100.96)
- BULLISH: Expecting earnings turnaround to 1.0% growth with 13.6% revenue growth
- WARNING: Composite score 39/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$85.13 -
$92.54
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$86.39
Resistance Level
$93.91
Current Trend
Strong Uptrend
Technical data as of
Aug 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
27.14
Wall Street Target
$100.96
(+10.2%)
Revenue Growth (YoY)
13.6%
Earnings Growth (YoY)
-25.4%
Profit Margin
15.4%
Valuation Premium vs History
+1.0% premium
PE vs Historical
27.1 vs 26.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.0%
(market-implied from PE analysis)
1-Year Target
$92.52
(+1%)
2-Year Target
$93.44
(+2%)
3-Year Target
$94.38
(+3%)
3-Yr Target (if PE normalizes)
(PE: 27â26)
PE COMPRESSION
$91.47
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 27.1, Growth: 12.6%)
$130.71
(+43%)
Base:
(SPY PE: 20.2, Growth: 12.6%)
$97.45
(+6%)
Bear:
(PE: 17.2, Growth: 12.6%)
$82.83
(-10%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (31x PE), but valuation improves significantly next year (27x PE) as earnings recover.
Forward PE: 30.67 | Forward EPS (Implied): $2.99
Bull Case
$110.61
(+21%)
Analyst growth 15.0%, PE expands to 32.2
Base Case
$91.60
(0%)
Market implied 0.0%, PE stable at 30.7
Bear Case
$70.07
(-24%)
Severe decline -15.0%, PE contracts to 27.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 16, 2026 2:59 AM ET
Data refreshes hourly during market hours. Next update: 3:59 AM
Data refreshes hourly during market hours. Next update: 3:59 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EW showing a specific setup today?
Insider Activity (6 Months)
1
Buys
8
Sells
Net
INSIDERS SELLING
Recent Transactions
Scott B Ullem
SELL
13000 shares
2026-04-09
Daniel J Lippis
SELL
1019 shares
2026-04-06
Donald E Bobo Jr
SELL
22680 shares
2026-04-02
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$63 | 33 SELL |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$382 | 48 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$93 | 28 SELL |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$98 | 41 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$118 | 29 SELL |
Advanced EW Option Strategies
Professional options setups generated by AI based on today's EW price and gamma walls.
